Metformin improves pregnancy outcomes in non-PCOS women with insulin resistance and recurrent implantation failure before frozen embryo transfer
Abstract
BACKGROUND: Recurrent implantation failure (RIF) leads to a significant waste of embryos and imposes substantial physical, emotional, and financial stress on patients. Given its complex and diverse etiology, identifying the underlying causes and developing effective interventions are crucial. Previous studies have shown that insulin resistance (IR) has negative effects on reproductive health, and metformin pre-treatment helps improve the pregnancy outcomes in IR patients. However, its role in patients with RIF remains unclear, especially in those without polycystic ovary syndrome (PCOS).
METHODS: A retrospective cohort study was conducted. The FET cycles of RIF patients without PCOS were stratified based on the presence or absence of IR. We used the univariate and multivariate generalized estimating equations (GEE) analysis to compare pregnancy outcomes between patients with IR and without IR, as well as between metformin-exposed and metformin-unexposed groups of RIF patients with IR.
RESULTS: In a subgroup of 941 cycles without IR and 145 cycles with IR, we found that patients with IR had a lower live birth rate (10.34% vs 20.94%, P = 0.0039) and a higher early miscarriage rate (52.77% vs 27.52%, P = 0.0034). After adjusting for potential confounders, the IR group still had a lower live birth rate (aOR = 0.5, 95% CI: 0.28-0.89, P = 0.019). In the subgroup of IR patients (n=330 cycles), patients in the metformin-exposed group (n=185 cycles) had a higher clinical pregnancy…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 330 participants or records.
Read the paper
Related studies
- Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis
- Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis
- Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules
- Regulation of Androgen Receptor Expression Alters AMPK Phosphorylation in the Endometrium: In Vivo and In Vitro Studies in Women with Polycystic Ovary Syndrome
- Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome
- Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.